title: Novel drugs against tuberculosis: a clinician's perspective.
abstract: The United Nations Millennium Development Goal of reversing the global spread of tuberculosis by 2015 has been offset by the rampant re-emergence of drug-resistant tuberculosis, in particular fluoroquinolone-resistant multidrug-resistant and extensively drug-resistant tuberculosis. After decades of quiescence in the development of antituberculosis medications, bedaquiline and delamanid have been conditionally approved for the treatment of drug-resistant tuberculosis, while several other novel compounds (AZD5847, PA-824, SQ109 and sutezolid) have been evaluated in phase II clinical trials. Before novel drugs can find their place in the battle against drug-resistant tuberculosis, linezolid has been compassionately used with success in the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis. This review largely discusses six novel drugs that have been evaluated in phase II and III clinical trials, with focus on the clinical evidence for efficacy and safety, potential drug interactions, and prospect for using multiple novel drugs in new regimens.
authors.affiliation: Division of Clinical Infectious Diseases, Research Center Borstel, German Center for Infection Research, Clinical Tuberculosis Center, Borstel, Germany.
authors.forename: Ioana Diana
authors.initials: ID
authors.lastname: Olaru
authors.affiliation: Task Applied Science, Karl Bremer Hospital, Bellville, Cape Town, South Africa.
authors.forename: Florian
authors.initials: F
authors.lastname: von Groote-Bidlingmaier
authors.affiliation: Division of Clinical Infectious Diseases, Research Center Borstel, German Center for Infection Research, Clinical Tuberculosis Center, Borstel, Germany.
authors.forename: Jan
authors.initials: J
authors.lastname: Heyckendorf
authors.affiliation: Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong, China.
authors.forename: Wing Wai
authors.initials: WW
authors.lastname: Yew
authors.affiliation: Division of Clinical Infectious Diseases, Research Center Borstel, German Center for Infection Research, Clinical Tuberculosis Center, Borstel, Germany International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany Dept of Internal Medicine, University of Namibia School of Medicine, Windhoek, Namibia Dept of Medicine, Karolinska Institute, Stockholm, Sweden clange@fz-borstel.de.
authors.forename: Christoph
authors.initials: C
authors.lastname: Lange
authors.affiliation: Tuberculosis and Chest Service, Dept of Health, Hong Kong, China.
authors.forename: Kwok Chiu
authors.initials: KC
authors.lastname: Chang
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D064687:Diarylquinolines / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005029:Ethylenediamines / Q000627:therapeutic use; D054908:Extensively Drug-Resistant Tuberculosis / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009593:Nitroimidazoles / Q000627:therapeutic use; D010080:Oxazoles / Q000627:therapeutic use; D023303:Oxazolidinones / Q000627:therapeutic use; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D064687:Diarylquinolines; D005029:Ethylenediamines; C506841:N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine; D009593:Nitroimidazoles; C516022:OPC-67683; D010080:Oxazoles; D023303:Oxazolidinones; C543015:PNU-100480; C410767:pretomanid; C493870:bedaquiline; D000218:Adamantane